|Prof. Nissim Benvenisty is the Herbert Cohn Chair in Cancer Research and the Director of The Azrieli Center for Stem Cells and Genetic Research at the Hebrew University. He is a member of the Board of Directors of the ISSCR, and serves on the editorial board of various stem cell-related journals. He was awarded several prizes among them the Foulkes Prize (London), the Hestrin Prize, the Teva Prize, the Kaye Prize and the Milken Prize.
Baoyang Hu, PhD
Institute of Zoology, CAS
|Dr. Baoyang Hu is a professor of stem cell and regenerative biology at the Institute of Zoology (IOZ), Chinese academy of Sciences (CAS). He is also the vice director of State Key Laboratory of Stem Cell and Reproductive Biology and the executive dean of medical school at the University of Chinese Academy of Sciences (UCAS). He is interested in transplantable neurons and glia for treating neurological diseases such as Parkinson's diseases and Alzheimer diseases.
Rudolf Jaenisch, MD
Whitehead Institute for Biomedical Research
|Rudolf Jaenisch is a Founding Member of the Whitehead Institute for Biomedical Research and a Professor of Biology at the Massachusetts Institute of Technology. He is a pioneer in making transgenic mice, some of which have produced important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities. These methods have been used to explore basic questions such as the role of DNA modification, genomic imprinting, X chromosome inactivation, and nuclear cloning. A major technology used in the lab are gene targeting approaches to edit DNA methylation as well as the sequences of target genes in ES cells and in mice. The laboratory is renowned for its expertise in reprogramming cell fate and in studying the myriad factors that contribute to the success and failure of this process. More recently the lab has used iPS cell technology to model human diseases such as Parkinson's, Alzheimer's and Autism.
Dr. Jaenisch is a Member of the National Academy of Sciences and the International Society for Stem Cell Research. In 1996 he was honored with the Boehringer Mannheim Molecular Bioanalytics Prize, in 2001 was the recipient of the first ever Peter Gruber Foundation Award in Genetics, in 2002 won the Robert Koch Prize for Excellence in Scientific Achievement and in 2011 was a recipient of the United States National Medal of Science. In 2014 he was president of the ISSCR
Michael Laflamme, MD, PhD
Toronto General Research Institute, University Health Network
|Dr. Michael Laflamme is the Robert McEwen Chair in Cardiac Regenerative Medicine at University Health Network and a Senior Scientist in the Toronto General Hospital Research Institute. His laboratory is focused on the development of pluripotent stem cell (PSC)-based therapies for ischemic heart disease, and they have show that the transplantation of human PSC-derived cardiomyocytes can partially "remuscularize" the infarct scar with electrically-integrated human myocardium in multiple preclinical models of myocardial infarction.
Wei Li, PhD
Institute of Zoology, CAS
|Wei Li is a principle investigator of Institute of Zoology, Chinese Academy of Sciences. His group is now interested in studying the mechanisms of genome stability of stem cells and cell fate decision, and developing new methods for genome engineering.
Pentao Liu, PhD
Wellcome Trust Sanger Institute
|Dr. Liu graduate from Henan Normal University. He obtained his M.Sc from Chinese Academy of Sciences and Institute of Genetics, and received a Ph.D. from Baylor College of Medicine. Dr. Liu did his postdoc training at National Cancer Institute. He joined the faculty of Wellcome Trust Sanger Institute in 2003 and is currently a Senior Group Leader. Dr. Liu's laboratory is working on stem cells, development, immunity and cancer.
Selected recent papers
1 Yang, J. et al. Establishment in Culture of Mouse Expanded Potential Stem Cells. Nature in press (2017).
2 Yu, Y. et al. Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway. Nature 539, 102-106 (2016).
3 Tsang, C. H. J. et al. Single-cell transcriptomic reconstruction reveals cell cycle and multi-lineage differentiation defects in Bcl11a-deficient hematopoietic stem cells. Genome Biology 16, 178 (2015).
4 Yu, Y. et al. The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. J Exp Med, doi:10.1084/jem.20142318 (2015).
5 Khaled, W. T. et al. BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. Nat Commun 6, 5987, doi:10.1038/ncomms6987 (2015).
6 Yang, J. et al. Signalling Through Retinoic Acid Receptors is Required for Reprogramming of Both Mouse Embryonic Fibroblast Cells and Epiblast Stem Cells to Induced Pluripotent Stem Cells. Stem Cells 33, 1390-1404, doi:10.1002/stem.1926 (2015).
7 Yu, Y. et al. Bcl11a is essential for lymphoid development and negatively regulates p53. J Exp Med. 209, 2467-2483, doi:10.1084/jem.20121846 (2012).
8 Wang, W. et al. Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1. PNAS 108, 18283-18288, doi:10.1073/pnas.1100893108 (2011).
9 Li, P. et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science 329, 85-89, doi:science.1188063 [pii]
Jose Maria Polo, PhD
|Jose Maria Polo graduated from Buenos Aires University as a Biochemist and obtained his PhD in 2008 at the Albert Einstein College of Medicine, New York under the supervision of Dr. Ari Melnick working on the transcriptional mechanism of BCL6. He then moved to Boston to the laboratory of Dr. Konrad Hochedlinger at the Harvard Stem Cell Institute to work on reprogramming of adult cells into iPS cells. In June 2011, Jose established his independent research group at Monash University to continue his work in reprogramming and epigenetics.
Stephanie Iris Protze, PhD
McEwen Centre for Regenerative Medicine
|Dr. Stephanie Protze earned her PhD in Cell Biology and Biomedicine from the International Max Planck Research School at the University of Dresden, Germany in 2012. For her Post Doctoral Fellowship she moved to the laboratory of Dr. Gordon Keller at the McEwen Centre for Regenerative Medicine at the University Health Network in Toronto, Canada during which she has specialized in human heart development and the generation of biological pacemakers using human pluripotent stem cells.
Jeremy Sugarman, MD, MPH, MA
Johns Hopkins University
|Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics and Medicine at the Johns Hopkins Berman Institute of Bioethics. He is an internationally recognized leader in the field of biomedical ethics with particular expertise in applying empirical methods for evaluating and analyzing bioethical issues. Dr. Sugarman is a member of ISSCR's Ethics and Public Policy Committees. He is co-chair of the Johns Hopkins' Institutional Stem Cell Research Oversight Committee.
Minoru Takasato, PhD
RIKEN Center for Developmental Biology
|Dr Minoru Takasato is a team leader of the laboratory of human organogenesis at RIKEN CDB since 2016, where he heads the kidney regeneration project. He is an expert in the directed differentiation of human pluripotent stem cells to kidney with his most recent work being published in Nature Cell Biology (2014) and Nature (2015). His most recent studies describe the generation of kidney organoids (mini-kidneys) from induced pluripotent stem cells.
Fuchou Tang, PhD
|Dr. Fuchou Tang set up his own lab at BIOPIC, Peking University in 2010 as a principal investigator. His lab focused on studying gene regulation network in human early embryos. His lab systematically developed single cell functional genomics sequencing technologies and used these cutting-edge methods to study the development of human early embryos. He has published more than twenty papers as corresponding authors in Cell, Nature, Science, Cell Stem Cell, Genome Research, Cell Research, etc.
Southwest Hospital, Third Military Medical University
|Zhengqin Yin MD & PhD
Professor and Director of Southwest Eye Hospital, Southwest Hospital, Third Military Medical University , Chongqing, China
Chair of the Key lab of Visual Damage and Regeneration & Restoration in Chongqing
Director of Southwest Eye Bank
Director of Chongqing Institute of Retina
Adjunct Professor of the University of New South Wales, Australia
Honorary Professor and Director of Ophthalmology of General Hospital of PLA, Beijing, China
Cellular therapy for retinal degeneration
Visual development and plasticity,
Bin Zhou, PhD
Shanghai Institute for Biological Sciences, Chinese Academy of Sciences
|Bin Zhou is a professor working in Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. His lab focuses on studying the cellular and molecular mechanism of cardiovascular development and regeneration. He is also interested in developing genetic lineage tracing and genetic manipulation technologies for more precise cell tracking in vivo and gene function studies. Using the state-of-the-art technologies, his lab recently unraveled the new developmental sources for coronary blood vessels and liver vasculature.